A perspective on the New American College of Cardiology/American Heart Association guidelines for cardiovascular risk assessment.

Pubmed ID: 25131696

Journal: Mayo Clinic proceedings

Publication Date: Sept. 1, 2014

Affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ.

MeSH Terms: Humans, Male, Adult, Female, Aged, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Risk Factors, Age Factors, Middle Aged, Risk Assessment, Sex Factors, Practice Guidelines as Topic, Decision Making, Racial Groups

Authors: Kullo IJ, Trejo-Gutierrez JF, Lopez-Jimenez F, Thomas RJ, Allison TG, Mulvagh SL, Arruda-Olson AM, Hayes SN, Pollak AW, Kopecky SL, Hurst RT

Cite As: Kullo IJ, Trejo-Gutierrez JF, Lopez-Jimenez F, Thomas RJ, Allison TG, Mulvagh SL, Arruda-Olson AM, Hayes SN, Pollak AW, Kopecky SL, Hurst RT. A perspective on the New American College of Cardiology/American Heart Association guidelines for cardiovascular risk assessment. Mayo Clin Proc 2014 Sep;89(9):1244-56. Epub 2014 Aug 12.

Studies:

Abstract

The recently published American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cardiovascular risk assessment provide equations to estimate the 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk in African Americans and non-Hispanic whites, include stroke as an adverse cardiovascular outcome, and emphasize shared decision making. The guidelines provide a valuable framework that can be adapted on the basis of clinical judgment and individual/institutional expertise. In this review, we provide a perspective on the new guidelines, highlighting what is new, what is controversial, and potential adaptations. We recommend obtaining family history of ASCVD at the time of estimating ASCVD risk and consideration of imaging to assess subclinical disease burden in patients at intermediate risk. In addition to the adjuncts for ASCVD risk estimation recommended in the guidelines, measures that may be useful in refining risk estimates include carotid ultrasonography, aortic pulse wave velocity, and serum lipoprotein(a) levels. Finally, we stress the need for research efforts to improve assessment of ASCVD risk given the suboptimal performance of available risk algorithms and suggest potential future directions in this regard.